G Metzgeroth

Overview

Explore the profile of G Metzgeroth including associated specialties, affiliations and a list of published articles.

Snapshot

Articles 20

Citations 401

Followers 0

Related Specialties

Hematology

Oncology

Cell Biology

Top 10 Co-Authors

A Reiter

R Hehlmann

A Hochhaus

N C P Cross

W-K Hofmann

O Maywald

J Schwaab

A Fabarius

U Berger

J Hastka

Published In

Leukemia

Cytopathology

Onkologie

Eur J Haematol

Internist (Berl)

Affiliations

Soon will be listed here.

Recent Articles

Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia

Jawhar M, Naumann N, Knut M, Score J, Ghazzawi M, Schneider B, et al.

Leukemia . 2017 Jul; 31(10):2271-2273. PMID: 28751768

No abstract available.

Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis

Jawhar M, Schwaab J, Hausmann D, Clemens J, Naumann N, Henzler T, et al.

Leukemia . 2016 Jul; 30(12):2342-2350. PMID: 27416984

We evaluated the impact of clinical and molecular characteristics on overall survival (OS) in 108 patients with indolent (n=41) and advanced systemic mastocytosis (SM) (advSM, n=67). Organomegaly was measured by...

Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)

Mossner M, Jann J, Nowak D, Platzbecker U, Giagounidis A, Gotze K, et al.

Leukemia . 2016 May; 30(9):1956-9. PMID: 27133825

No abstract available.

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis

Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, et al.

Leukemia . 2015 Oct; 30(1):136-43. PMID: 26464169

Most patients with KIT D816V(+) advanced systemic mastocytosis (SM) are characterized by somatic mutations in additional genes. We sought to clarify the prognostic impact of such mutations. Genotype and clinical...

[Iron deficiency anemia and anemia of chronic disorders]

Metzgeroth G, Hastka J

Internist (Berl) . 2015 Aug; 56(9):978-88. PMID: 26228317

Hypochromic-microcytic anemias are characterized by a hemoglobin deficiency of the erythrocytes. The main reason for the insufficient hemoglobin synthesis is, with exception of thalassemia and a few other rare conditions,...

Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event

Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny H, Metzgeroth G, et al.

Leukemia . 2015 Jan; 29(5):1115-22. PMID: 25567135

To explore the molecular profile and its prognostic implication in systemic mastocytosis (SM), we analyzed the mutation status of granulocyte-macrophage colony-forming progenitor cells (CFU-GM) in patients with KIT D816V(+) indolent...

[Systemic mastocytosis]

Metzgeroth G, Schwaab J, Reiter A

Dtsch Med Wochenschr . 2014 Jul; 139(31-32):1572-5. PMID: 25076308

No abstract available.

Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase

Metzgeroth G, Schwaab J, Gosenca D, Fabarius A, Haferlach C, Hochhaus A, et al.

Leukemia . 2013 Apr; 27(11):2254-6. PMID: 23615556

No abstract available.

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation

Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, Walz C, et al.

Leukemia . 2011 Aug; 26(1):162-4. PMID: 21818111

No abstract available.